Low-density lipoprotein cholesterol goals in the secondary prevention of cardiovascular diseases in the Indian population-Is 30 the new 70?

J Clin Lipidol. 2020 Mar-Apr;14(2):173-175. doi: 10.1016/j.jacl.2020.01.011. Epub 2020 Jan 30.

Authors

Vijay Nambi¹, Geeta Sikand², Dinesh Kalra³, Krishnaswami Vijayaraghavan⁴

Affiliations

¹ Michael E. DeBakey Veterans Affairs Hospital and Baylor College of Medicine, Houston, TX, USA.
² University of California Irvine Heart Disease Prevention Program, Irvine, CA, USA.
³ Lipid Clinic, Division of Cardiology, Rush University Medical Center, Chicago, IL, USA.
⁴ Abrazo Health Network and University of Arizona, Phoenix, AZ, USA. Electronic address: kvijaymd@gmail.com.

PMID: 32098725
DOI: 10.1016/j.jacl.2020.01.011

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antibodies, Monoclonal
Cardiovascular Diseases*
Cholesterol, LDL
Consensus
Goals
Humans
Hyperlipoproteinemia Type II*
India
Proprotein Convertase 9
Secondary Prevention

Substances

Antibodies, Monoclonal
Cholesterol, LDL
PCSK9 protein, human
Proprotein Convertase 9